ENZO BIOCHEM INC's ticker is ENZ and the CUSIP is 294100102. A total of 89 filers reported holding ENZO BIOCHEM INC in Q4 2015. The put-call ratio across all filers is 1.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $133,000 | -84.4% | 25,557 | -83.6% | 0.12% | -85.6% |
Q1 2018 | $852,000 | -34.0% | 155,486 | -1.9% | 0.87% | -33.0% |
Q4 2017 | $1,291,000 | -25.6% | 158,427 | -4.4% | 1.29% | -18.7% |
Q3 2017 | $1,735,000 | -21.1% | 165,727 | -16.8% | 1.59% | -19.2% |
Q2 2017 | $2,198,000 | +8.2% | 199,132 | -17.9% | 1.97% | -0.9% |
Q1 2017 | $2,031,000 | +38.1% | 242,640 | +14.5% | 1.98% | +27.8% |
Q4 2016 | $1,471,000 | +24.6% | 211,974 | -8.7% | 1.55% | +33.1% |
Q3 2016 | $1,181,000 | -71.1% | 232,099 | -66.1% | 1.17% | -46.3% |
Q2 2016 | $4,086,000 | +84.1% | 684,359 | +40.3% | 2.17% | +79.6% |
Q1 2016 | $2,219,000 | -16.5% | 487,724 | -17.5% | 1.21% | -7.4% |
Q4 2015 | $2,659,000 | +25.2% | 590,874 | -11.8% | 1.31% | +14.4% |
Q3 2015 | $2,124,000 | -14.8% | 670,027 | -18.5% | 1.14% | +2.9% |
Q2 2015 | $2,492,000 | +29.7% | 822,522 | +26.3% | 1.11% | +30.4% |
Q1 2015 | $1,922,000 | -33.3% | 651,415 | +0.3% | 0.85% | -38.6% |
Q4 2014 | $2,883,000 | -15.1% | 649,400 | -1.5% | 1.39% | -17.5% |
Q3 2014 | $3,397,000 | +37.0% | 659,620 | +39.7% | 1.68% | +47.6% |
Q2 2014 | $2,479,000 | – | 472,285 | – | 1.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARBERT FUND ADVISORS, INC. | 5,169,337 | $17,420,000 | 25.49% |
Roumell Asset Management, LLC | 1,236,309 | $4,166,000 | 9.86% |
Evermore Global Advisors, LLC | 3,587,251 | $12,089,000 | 2.28% |
CORRADO ADVISORS, LLC | 198,544 | $669,000 | 0.60% |
Fondren Management LP | 175,863 | $593,000 | 0.56% |
MARATHON CAPITAL MANAGEMENT | 247,130 | $832,000 | 0.34% |
KEMPNER CAPITAL MANAGEMENT INC. | 95,476 | $322,000 | 0.21% |
EAM Investors, LLC | 178,939 | $603,000 | 0.15% |
Leap Investments LP | 11,811 | $40,000 | 0.05% |
GSA CAPITAL PARTNERS LLP | 75,900 | $256,000 | 0.03% |